Search Results 1751-1760 of 11638 for total t4

1. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) - Mayo Clinic

   Have total bilirubin <2.0 mg/dL; Have aspartate aminotransferase and alanine aminotransferase <3 times the upper limit of normal; Have serum creatinine ≤3 ...

2. Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer - Mayo Clinic

   Computed tomography (CT) scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body positron emission tomography (PET)/CT. History ...

3. Clinical Trials - Continued Access To PREVAIL (CAP2)

   The subject is unable to complete follow-up visits for the duration of the study. Echo Exclusion Criteria: A subject is excluded from the study if any of the ...

4. Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil - Mayo Clinic

   The patient can complete a baseline six-minute walk distance (6MWD) ≥ 150 m. The patient has had evidence of FEV1 ≥ 60% and FEV1/FVC ratio ≥ 60% during ...

5. A Study Using the New TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients with Metastatic, Persistent, Recurrent, or Progressive Solid Tumors - Mayo Clinic

   Total bilirubin =< 1.5 X upper limit of normal (ULN) unless history of Gilbert's syndrome documented prior to first-line treatment of cancer and other liver ...

6. Clinical Research Study With Clazosentan To Evaluate Its Effects On Preventing Complications Due To The Narrowing Of The Blood Vessels (Vasospasm) In The Brain, Caused By Bleeding Onto The Surface Of The Brain (REACT) - Mayo Clinic

   Participation eligibility · Subjects with total bilirubin > 2 times the upper limit of normal, and/or a known diagnosis or clinical suspicion of liver cirrhosis ...

7. A Study To Evaluate Intravenous Iloprost In Subjects With Symptomatic Raynaud's Phenomenon Secondary To Systemic Sclerosis - Mayo Clinic

   Subjects must complete a minimum of 80% of the daily ePRO diary entry during the baseline period; Female subjects of childbearing potential and male subjects ...

8. A Global Study To Assess The Drug Dynamics, Efficacy, And Safety Of GZ/SAR402671 In Parkinson's Disease Patients Carrying A Glucocerebrosidase (GBA) Gene Mutation - Mayo Clinic

   Part 2: - To demonstrate overall safety and tolerability of GZ/SAR4027671 administered orally in early-stage Parkinson's disease patients carrying a GBA ...

9. Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery - Mayo Clinic

   Serum creatinine < 2.0 mg/dL; Total bilirubin < 2 x the institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) or alanine ...

10. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (enrollment by invitation only) - Mayo Clinic

    Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with ...